Target intelligence / Profile preview

Vaginal immune system (VIS)

Target
VIS
Molecular classification
Other
01

Overview

The vaginal immune system is a complex, compartmentalized component of the mucosal immune system designed to protect the female reproductive tract from pathogens while maintaining tolerance to commensal microbes and sperm (Wira et al., 2005, Nature Reviews Immunology). It consists of physical barriers, such as the stratified squamous epithelium, and a diverse array of innate and adaptive immune components, including neutrophils, macrophages, T cells, and B cells (Hickey et al., 2011, Molecular Human Reproduction). The system is heavily influenced by hormonal fluctuations during the menstrual cycle and the presence of a healthy, Lactobacillus-dominant microbiome, which maintains an acidic pH through lactic acid production (Anahtar et al., 2018, NIH). Dysregulation of this system, often characterized by a shift in microbial diversity or increased pro-inflammatory cytokines, is linked to increased susceptibility to sexually transmitted infections, including HIV (NIH, 2021). While not a single molecular target, various components of the vaginal immune system are targeted by microbicides, vaccines, and probiotics to enhance local defense mechanisms and prevent disease transmission (PubChem, 2023). Understanding the interplay between the microbiome and local immunity is critical for developing effective topical therapeutics and preventative measures for reproductive health.

Other names
Female reproductive tract immune systemVaginal mucosal immunityVaginal mucosal immune systemLower female reproductive tract immune environment
02

Mechanism of action

Modulation of the local mucosal environment through the regulation of cytokine production, recruitment of innate and adaptive immune cells, and maintenance of commensal microbiota to prevent pathogen colonization and enhance epithelial barrier integrity.

03

Biological functions

Immune responseMucosal protectionMicrobiome maintenancePathogen defenseImmune tolerance
04

Disease associations

InfectionInflammationCancerHuman immunodeficiency virus (HIV) infectionSexually transmitted infections (STIs)Bacterial vaginosis
05

Safety considerations

Risk of vaginal dysbiosisIncreased susceptibility to infections if the mucosal barrier is disruptedLocal tissue irritation or inflammationPotential for systemic absorption of locally applied agents
06

Interacting drugs

Tenofovir

4 more in the full profile.

07

Biomarkers

Vaginal pHLactobacillus concentrationInterleukin-1 beta (IL-1b)Interleukin-6 (IL-6)Interleukin-8 (IL-8)Secretory IgA

Beyond the preview

Go deeper on Vaginal immune system (VIS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaginal immune system (VIS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call